BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:GSK 5733584 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of GSK 5733584\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06431594-9165@assetmemo.bio
DTSTAMP:20261121T010441Z
DTSTART;VALUE=DATE:20270922
DTEND;VALUE=DATE:20270923
SUMMARY:GSK 5733584: Phase 1 readout est. (NCT06431594)
DESCRIPTION:GSK 5733584\, phase 1.\nStudy: A Study to Evaluate the Safety\,
 Tolerability\, Pharmacokinetics and Clinical Activity of Mocertatug Rezete
 can for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)\nE
 stimated primary completion: 22 September 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/gsk-5733584#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06431594
URL:https://assetmemo.bio/drug/gsk-5733584#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07286331-9165@assetmemo.bio
DTSTAMP:20261121T010441Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:GSK 5733584: Phase 3 readout est. (NCT07286331)
DESCRIPTION:GSK 5733584\, phase 3.\nStudy: A Study to Investigate Mocertatu
 g Rezetecan Compared With Chemotherapy in Participants With Endometrial Ca
 ncer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometri
 al01)\nEstimated primary completion: 29 February 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/gsk-5733584#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07286331
URL:https://assetmemo.bio/drug/gsk-5733584#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07684599-9165@assetmemo.bio
DTSTAMP:20261121T010441Z
DTSTART;VALUE=DATE:20290723
DTEND;VALUE=DATE:20290724
SUMMARY:GSK 5733584: Phase 3 readout est. (NCT07684599)
DESCRIPTION:GSK 5733584\, phase 3.\nStudy: A Study to Investigate Mocertatu
 g Rezetecan as Maintenance Treatment for Participants With MMRp Endometria
 l Cancer (BEHOLD-Endometrial02)\nEstimated primary completion: 23 July 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/gsk-5733584#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07684599
URL:https://assetmemo.bio/drug/gsk-5733584#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07694427-9165@assetmemo.bio
DTSTAMP:20261121T010441Z
DTSTART;VALUE=DATE:20290906
DTEND;VALUE=DATE:20290907
SUMMARY:GSK 5733584: Phase 3 readout est. (NCT07694427)
DESCRIPTION:GSK 5733584\, phase 3\, Ovarian Cancer.\nStudy: Mo-Rez in First
 - Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficien
 t Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]\nEstimated primary comple
 tion: 6 September 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/gsk-5733584#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07694427
URL:https://assetmemo.bio/drug/gsk-5733584#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07684612-9165@assetmemo.bio
DTSTAMP:20261121T010441Z
DTSTART;VALUE=DATE:20300521
DTEND;VALUE=DATE:20300522
SUMMARY:GSK 5733584: Phase 3 readout est. (NCT07684612)
DESCRIPTION:GSK 5733584\, phase 3\, Ovarian Cancer.\nStudy: A Study to Inve
 stigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doubl
 et With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer
  (BEHOLD-Ovarian02)\nEstimated primary completion: 21 May 2030. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/gsk-5733584#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07684612
URL:https://assetmemo.bio/drug/gsk-5733584#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07286266-9165@assetmemo.bio
DTSTAMP:20261121T010441Z
DTSTART;VALUE=DATE:20300722
DTEND;VALUE=DATE:20300723
SUMMARY:GSK 5733584: Phase 3 readout est. (NCT07286266)
DESCRIPTION:GSK 5733584\, phase 3\, Ovarian Cancer.\nStudy: A Study to Inve
 stigate Mocertatug Rezetecan Compared With Standard of Care in Participant
 s With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)\nEstimated pri
 mary completion: 22 July 2030. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/gsk-5733584#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07286266
URL:https://assetmemo.bio/drug/gsk-5733584#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01042379-9165@assetmemo.bio
DTSTAMP:20261121T010441Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:GSK 5733584: Phase 2 readout est. (NCT01042379)
DESCRIPTION:GSK 5733584\, phase 2.\nStudy: I-SPY TRIAL: Neoadjuvant and Per
 sonalized Adaptive Novel Agents to Treat Breast Cancer\nEstimated primary 
 completion: December 2030. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/gsk-5733584#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT01042379
URL:https://assetmemo.bio/drug/gsk-5733584#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
